← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA3618.1x25.1x36.8x
EV / LTM revenue721.5x2.9x5.4x
Premium to unaffected price6423%37%54%
Premium to 30-day VWAP1129%42%48%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
07142009: 1 deals, 0 clean on every measure200912010: 14 deals, 1 clean on every measure2010142011: 9 deals, 5 clean on every measure201192012: 4 deals, 4 clean on every measure201242013: 6 deals, 5 clean on every measure201362014: 5 deals, 5 clean on every measure201452015: 3 deals, 2 clean on every measure201532016: 8 deals, 8 clean on every measure201682017: 7 deals, 7 clean on every measure201772018: 6 deals, 6 clean on every measure201862019: 3 deals, 3 clean on every measure201932020: 6 deals, 5 clean on every measure202062021: 7 deals, 7 clean on every measure202172022: 3 deals, 3 clean on every measure202232023: 4 deals, 4 clean on every measure202342024: 8 deals, 7 clean on every measure202482025: 11 deals, 11 clean on every measure2025112026: 4 deals, 3 clean on every measure20264
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 25.3x median across 21 dealsHealthcare25.3xn=21Industrials: 21.4x median across 14 dealsIndustrials21.4xn=14
Deals by sector
Healthcare: 75 dealsHealthcare75Industrials: 32 dealsIndustrials32Technology: 2 dealsTechnology2
Deals by buyer type
Financial sponsor: 5 dealsFinancial sponsor5Strategic: 70 dealsStrategic70Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 33 dealsUnclassified33
Deals by enterprise value
Under $250m: 47 dealsUnder $250m47$250m to $1bn: 31 deals$250m to $1bn31$1bn to $5bn: 24 deals$1bn to $5bn24$5bn to $20bn: 6 deals$5bn to $20bn6Over $20bn: 0 dealsOver $20bn0Not computed: 1 dealsNot computed1
Deals by industry code
Business Services & Software: 390 dealsBusiness Services & Sof…390Chemicals, Pharmaceuticals & Allied Products: 204 dealsChemicals, Pharmaceutic…204Electronics & Electrical Equipment: 149 dealsElectronics & Electrica…149Instruments, Medical Devices & Optical Goods: 109 dealsInstruments, Medical De…109Holding & Other Investment Offices: 96 dealsHolding & Other Investm…96Electric, Gas & Sanitary Services: 79 dealsElectric, Gas & Sanitar…79Insurance Carriers: 72 dealsInsurance Carriers72Industrial Machinery & Computers: 69 dealsIndustrial Machinery & …69Health Services: 69 dealsHealth Services69Communications: 65 dealsCommunications65
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Conformis Inc
2023-06-22 · Public merger · $2.27 a share
Not named in the filing
Unclassified
Healthcare-$0mn.a.0.0x
50%
93% to VWAP
DEFM14A
All cash
Cardiovascular Systems Inc
2023-02-08 · Public merger · $20.00 a share
Abbott Laboratories
Strategic
Healthcare$707mn.a.3.0x
50%
44% to VWAP
DEFM14A
All cash
Apollo Endosurgery, Inc.
2022-11-29 · Public merger · $10.00 a share
Boston Scientific
Strategic
Healthcare$383mn.a.5.3x
67%
DEFM14A
All cash
Cyberoptics Corp
2022-08-07 · Public merger · $54.00 a share
Nordson Corporation
Strategic
Industrials$380m18.7x3.7x
n.a.
DEFM14A
All cash
Natus Medical Inc
2022-04-17 · Public merger · $33.50 a share
Prince Parent Inc.
Unclassified
Healthcare$1.1bn21.0x2.2x
29%
DEFM14A
All cash
Hill-Rom Holdings, Inc.
2021-09-01 · Public merger · $156.00 a share
Baxter International Inc.
Strategic
Healthcare$12bnn.a.4.0x
17%
DEFM14A
All cash
Intersect ENT, Inc.
2021-08-06 · Public merger · $28.25 a share
Medtronic, Inc.
Strategic
Healthcare$883mn.a.8.6x
n.a.
DEFM14A
All cash
Exfo Inc.
2021-07-16 (filed) · Take-private · $6.00 a share
Board book on file →
Not named in the filing
Unclassified
Industrialsn.a.n.a.n.a.
62%
SC 13E3
All cash
Gi Dynamics, Inc.
2021-06-15 (filed) · Take-private · $0.06 a share
Crystal Amber Fund LTD
Financial sponsor
Healthcare$8mn.a.n.a.
n.a.
SC 13E3
All cash
Soliton, Inc.
2021-05-08 · Public merger · $22.60 a share
AbbVie Inc.
Strategic
Healthcare$457mn.a.n.a.
26%
34% to VWAP
DEFM14A
All cash
Luminex Corp
2021-04-11 · Public merger · $37.00 a share
DiaSorin S.p.A.
Strategic
Healthcare$1.7bn20.1x3.9x
n.a.
DEFM14A
All cash
Cantel Medical LLC
2021-01-12 · Public merger · $16.93 a share
STERIS plc
Strategic
Healthcare$1.3bn11.3xn.a.
n.a.
15% to VWAP
DEFM14A
All cash
Mikros Systems Corp
2020-11-12 · Public merger · $0.13 a share
McKean Defense Group, Inc.
Strategic
Industrials$3m5.0x0.4x
13%
14% to VWAP
DEFM14A
All cash
Telenav, Inc.
2020-11-02 · Take-private · $4.80 a share
Digital Mobile Venture LTD
Strategic
Technology$129m16.0x0.5x
20%
SC 13E3
All cash
Varian Medical Systems Inc
2020-08-02 · Public merger · $177.50 a share
Falcon Sub Inc.
Strategic
Healthcare$16bn40.3x5.0x
24%
DEFM14A
All cash
Liquidia Technologies Inc
2020-06-29 · Public merger · $4.77 a share
PBM RG Holdings, LLC
Strategic
Healthcare$110mn.a.13.5x
n.a.
DEFM14A
All cash
TearLab Corp
2020-05-11 · Public merger · $0.06 a share
Held out of the multiples: EV / LTM EBITDA 95.9x outside 1x to 75x
Accelmed Partners II LP
Financial sponsor
Healthcare$77m95.9x3.5x
n.a.
DEFM14C
All cash
Wright Medical Group N.V.
2020-03-20 (filed) · Public merger · $30.75 a share
Not named in the filing
Unclassified
Healthcare$5.0bn65.5x5.4x
n.a.
50% to VWAP
DEFM14A
All cash
Corindus Vascular Robotics, Inc.
2019-08-07 · Public merger · $4.28 a share
Siemens Medical Solutions USA, Inc.
Strategic
Healthcare$873mn.a.57.5x
77%
DEFM14A
All cash
Sierra Monitor Corp /Ca/
2019-03-28 · Public merger · $3.25 a share
Not named in the filing
Unclassified
Industrials$30m60.6x1.4x
51%
DEFM14C
All cash
Cas Medical Systems Inc
2019-02-11 · Public merger · $2.45 a share
Edwards Lifesciences Holding, Inc., Inc.
Strategic
Healthcare$77mn.a.3.5x
56%
DEFM14A
All cash
Pacific Biosciences of California, Inc.
2018-11-01 · Public merger · $8.00 a share
Illumina, Inc.
Strategic
Industrials$1.1bnn.a.13.0x
n.a.
DEFM14A
All cash
Esterline Technologies Corp
2018-10-09 · Public merger · $122.50 a share
Transdigm Group Incorporated
Strategic
Industrials$3.9bnn.a.1.9x
n.a.
DEFM14A
All cash
K2m Group Holdings, Inc.
2018-08-29 · Public merger · $27.50 a share
Stryker Corporation
Strategic
Healthcare$1.1bnn.a.4.2x
26%
DEFM14A
All cash
Abaxis Inc
2018-05-15 · Public merger · $83.00 a share
Zoetis Inc.
Strategic
Industrials$1.7bn36.8x7.0x
15%
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More